German panel endorses GSK, Pfizer RSV vaccines for elderly
FRANKFURT, Aug 8 (Reuters) -Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV.
The panel of independent experts known as STIKO said in a statement that one shot, either Pfizer's PFE.N Abrysvo or Arexvy by GSK GSK.L, should be administered ideally in September or October before the cold season.
New pharmaceutical protection against RSV, a virus potentially dangerous for infants and the elderly, has provided a global sales boost for the companies that won regulatory approval.
STIKO said in June all infants in the country should receive AstraZeneca AZN.L and Sanofi's SASY.PA jointly owned antibody therapy to protect them against RSV.
STIKO advice is widely followed by family doctors in Germany, Europe's largest pharmaceutical market.
It also said that people as young as 60 with certain chronic diseases should also get an RSV vaccine shot.
More health data will be needed to decide whether future booster shots should be given after one vaccination, STIKO added.
Reporting by Ludwig Burger
Editing by Madeline Chambers
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
